Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1071-1078 , December 2007

Antiphospholipid syndrome (APS): Where does it come from?

  • Yehuda Shoenfeld, MD, FRCP (Hon.) (Professor Incumbent of the Laura Schwartz Kipp Chair for Research of Autoimmune Diseases)

      Affiliations

    • Corresponding Author InformationCorresponding author. Center for Autoimmune Diseases, Department of Medicine ‘B’, Sheba Medical Center, Tel-Hashomer, 52621, Israel. Tel.: +972 3 5302652; Fax: +972 3 5352855.

References 

  1. Asherson RA, Cervera R, Piette JC, et al. Milestones in the antiphospholipid syndrome. In:  Asherson RA,  Cervera R,  Piette JC editor. The antiphospholipid syndrome II – autoimmune thrombosis. Amsterdam: Elsevier; 2002;
  2. Sherer Y, Shoenfeld Y. The antiphospholipid syndrome- an entity to be expanded. American Journal of Reproductive Immunology. 1999;41:113–116
  3. Twig G, Sherer Y, Blank M, et al. Antiphospholipid syndrome- pathophysiology. In:  Carp HJA editors. Recurrent pregnancy loss- causes, controversies and treatment. London, UK: Informa; 2007;p. 107–113
  4. Blank M, Cohen J, Toder V, et al. Induction of antiphospholipid syndrome in naïve mice with mouse lupus monoclonal and human poly-clonal antiphospholipid antibodies. Proceedings of the National Academy of Sciences of the United States of America. 1991;88:3069–3073
  5. Kruase I, Leibovici L, Blank M, et al. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus. 2007;16:176–180
  6. Blank M, Shoenfeld Y. Antiphospholipid syndrome infectious origin. Journal of Clinical Immunology. 2004;24:12–23
  7. Levy Y, Almog O, Gorshtein A, et al. The environment and antiphospholipid syndrome. Lupus. 2006;15:784–790
  8. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Seminars in Arthritis and Rheumatism. 2002;31:256–263
  9. Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Current Rheumatology Reports. 2001;3:277–285
  10. Orts J, Colomina A, Zuniga A, et al. Cytomegalovirus infection and antiphospholipid syndrome in humans. Arthritis & Rheumatism. 2003;48:3296–3297
  11. Asano Y, Sarukawa M, Idezuki T, et al. Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection. Clinical Rheumatology. 2006;25:585–587
  12. Reitblat T, Drogenikov T, Sigalov I, et al. Transient anti-cardiolipin antibody syndrome in a patient with parvovirus B19 infection. American Journal of Medicine. 2000;109:512–513
  13. Guerin J, Feighery EC. Anti-beta-2-glycoprotein-I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31:109–116
  14. Guglielmone H, Vitozzi S, Elbarcha O, et al. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Annals of the Rheumatic Diseases. 2001;60:500–504
  15. Espinosa G, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome and sepsis: a common link?. The Journal of Rheumatology. 2007;34:923–926
  16. Asherson RA. The catarstrophic antiphospholipid syndrome. The Journal of Rheumatology. 1992;19:508–512
  17. Blank M, Shoenfeld Y. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clinical Immunology. 2004;112:190–199
  18. Shoenfeld Y, Krause I, Kvapil F, et al. Prevalence and clinical correlations of antibodies against six beta-2-glycoprotein-I related peptides in the antiphospholipid syndrome. Journal of Clinical Immunology. 2003;23:377–383
  19. Blank M, Shoenfeld Y, Cabilly S, et al. Prevention of antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:5164–5168
  20. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta-2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. The Journal of Clinical Investigation. 2002;109:797–804
  21. Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis & Rheumatism. 2002;46:545–552
  22. Gharavi EE, Chaimovich H, Cucurull E, et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus. 1999;8:449–455
  23. Shoenfeld Y, Aharon-Maor A, Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clinical and Experimental Rheumatology. 2000;18:181–184
  24. Martinuc PJ, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clinical and Experimental Immunology. 2005;142:377–380
  25. Mormile R, D'Alterio V, Treccagnoli G, et al. Henoch-Schonlein purpura with antiphospholipid antibodies after influenza vaccination: how fearful is it in children?. Vaccine. 2004;23:567–568
  26. Lillicrap DP, Pinto M, Benford K, et al. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. American Journal of Clinical Pathology. 1990;93:771–775
  27. Merrill JT, Shen C, Gugnani M, et al. High prevalence of antiphospholipid antibodies in patients taking procainamide. The Journal of Rheumatology. 1997;24:1083–1088
  28. de Groot PG, Horbach DA, Derksen RH. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus. 1996;5:488–493
  29. Pengo V, Biasiolo A, Brocco T, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thrombosis and Haemostasis. 1996;75:721–724
  30. Cuadrado MJ, Lopez-Pedrera C, Khamashta MA, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis & Rheumatism. 1997;40:834–841
  31. Reverter JC, Tassies D, Font J, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis & Rheumatism. 1998;41:1420–1427
  32. Font J, Espinosa G, Tassies D, et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. Arthritis & Rheumatism. 2002;46:3283–3289
  33. Kornberg A, Renaudineau Y, Blank M, et al. Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. The Israel Medical Association Journal. 2000;(2 supplement):27–31
  34. Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. Journal of Autoimmunity. 2000;15:237–240
  35. Lellouche F, Martinuzzo M, Said P, et al. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood. 1991;78:2894–2899
  36. Fishman P, Falach-Vaknin E, Sredni B, et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. American Journal of Reproductive Immunology. 1996;35:80–84
  37. Fishman P, Falach-Vaknin E, Sredni B, et al. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. The Journal of Rheumatology. 1995;22:1086–1090
  38. Ornoy A, Yacobi S, Matalon ST, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus. 2003;12:573–578
  39. Matalon ST, Shoenfeld Y, Blank M, et al. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. American Journal of Reproductive Immunology. 2004;51:144–151
  40. Bernstein PS, Divon MY. Etiologies of fetal growth restriction. Clinical Obstetrics and Gynecology. 1997;40:723–729
  41. Holers VM, Girardi G, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. The Journal of Experimental Medicine. 2002;195:211–220
  42. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. The Journal of Clinical Investigation. 2003;112:1639–1641
  43. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 2000;39:421–426

PII: S1521-6942(07)00108-8

doi: 10.1016/j.berh.2007.09.005

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 6 , Pages 1071-1078 , December 2007

Article Tools